Compare CPAC & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAC | SGP |
|---|---|---|
| Founded | 1949 | 2019 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 968.0M |
| IPO Year | 2003 | 2026 |
| Metric | CPAC | SGP |
|---|---|---|
| Price | $12.55 | $27.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $12.90 | ★ $45.00 |
| AVG Volume (30 Days) | 40.6K | ★ 64.3K |
| Earning Date | 04-24-2026 | 05-15-2026 |
| Dividend Yield | ★ 5.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.25 | $17.06 |
| 52 Week High | $12.74 | $30.56 |
| Indicator | CPAC | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 57.95 |
| Support Level | $11.56 | $25.00 |
| Resistance Level | N/A | $27.53 |
| Average True Range (ATR) | 0.26 | 1.29 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 98.25 | 42.92 |
Cementos Pacasmayo SAA is a Peruvian cement company, and only cement manufacturer serving in the northern region of Peru. It produce, distribute and sell cement and cement-related materials, such as precast products and ready-mix concrete. Its products are mainly used in construction, which has been one of the fastest growing segments of the Peruvian economy in recent years. It also produce and sell quicklime for use in mining operations. It also provide transportation services. It has three operating segments cement, concrete, mortar, pavement and precast; quicklime; and sales of construction supplies. The majority of profit comes from Cement segment. Peru's cement production is into three regions northern region, central region, including Lima's metropolitan area, and southern region.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.